vs
MESA LABORATORIES INC（MLAB）とRE/MAX Holdings, Inc.（RMAX）の財務データ比較。上の社名をクリックして会社を切り替えられます
RE/MAX Holdings, Inc.の直近四半期売上が大きい（$71.1M vs $65.1M、MESA LABORATORIES INCの約1.1倍）。MESA LABORATORIES INCの純利益率が高く（5.6% vs 2.0%、差は3.5%）。MESA LABORATORIES INCの前年同期比売上増加率が高い（3.6% vs -1.8%）。RE/MAX Holdings, Inc.の直近四半期フリーキャッシュフローが多い（$33.5M vs $18.0M）。過去8四半期でMESA LABORATORIES INCの売上複合成長率が高い（5.1% vs -4.7%）
メサラボラトリーズ社は、品質管理、校正、モニタリング向け専門機器及び関連サービスの開発・製造・販売を事業としています。医療、製薬、食品飲料、産業衛生、環境試験分野を中心に、世界中の顧客の規制遵守と運用安全のニーズに応えています。
RE/MAXは世界的に有名な不動産フランチャイズ企業で、事業は100以上の国と地域に展開しています。傘下には数千の店舗があり、10万人を超える不動産エージェントが在籍しており、国際的な不動産仲介業界で高い知名度と市場影响力を持っています。
MLAB vs RMAX — 直接比較
損益計算書 — Q3 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $65.1M | $71.1M |
| 純利益 | $3.6M | $1.4M |
| 粗利率 | 64.2% | — |
| 営業利益率 | 12.2% | 13.1% |
| 純利益率 | 5.6% | 2.0% |
| 売上前年比 | 3.6% | -1.8% |
| 純利益前年比 | 316.6% | -75.2% |
| EPS（希薄化後） | $0.65 | — |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $65.1M | $71.1M | ||
| Q3 25 | $60.7M | $73.2M | ||
| Q2 25 | $59.5M | $72.8M | ||
| Q1 25 | $62.1M | $74.5M | ||
| Q4 24 | $62.8M | $72.5M | ||
| Q3 24 | $57.8M | $78.5M | ||
| Q2 24 | $58.2M | $78.5M | ||
| Q1 24 | $58.9M | $78.3M |
| Q4 25 | $3.6M | $1.4M | ||
| Q3 25 | $2.5M | $4.0M | ||
| Q2 25 | $4.7M | $4.7M | ||
| Q1 25 | $-7.1M | $-2.0M | ||
| Q4 24 | $-1.7M | $5.8M | ||
| Q3 24 | $3.4M | $966.0K | ||
| Q2 24 | $3.4M | $3.7M | ||
| Q1 24 | $-254.6M | $-3.4M |
| Q4 25 | 64.2% | — | ||
| Q3 25 | 61.5% | — | ||
| Q2 25 | 62.0% | — | ||
| Q1 25 | 61.8% | — | ||
| Q4 24 | 63.3% | — | ||
| Q3 24 | 61.3% | — | ||
| Q2 24 | 64.0% | — | ||
| Q1 24 | 62.1% | — |
| Q4 25 | 12.2% | 13.1% | ||
| Q3 25 | 7.8% | 25.0% | ||
| Q2 25 | 5.1% | 19.3% | ||
| Q1 25 | 2.4% | 7.2% | ||
| Q4 24 | 9.2% | 5.9% | ||
| Q3 24 | 6.1% | 19.4% | ||
| Q2 24 | 9.6% | 20.6% | ||
| Q1 24 | -460.6% | 5.8% |
| Q4 25 | 5.6% | 2.0% | ||
| Q3 25 | 4.1% | 5.4% | ||
| Q2 25 | 8.0% | 6.4% | ||
| Q1 25 | -11.4% | -2.6% | ||
| Q4 24 | -2.7% | 8.0% | ||
| Q3 24 | 5.9% | 1.2% | ||
| Q2 24 | 5.8% | 4.7% | ||
| Q1 24 | -432.2% | -4.3% |
| Q4 25 | $0.65 | — | ||
| Q3 25 | $0.45 | — | ||
| Q2 25 | $0.85 | — | ||
| Q1 25 | $-1.30 | — | ||
| Q4 24 | $-0.31 | — | ||
| Q3 24 | $0.63 | — | ||
| Q2 24 | $0.62 | — | ||
| Q1 24 | $-47.26 | — |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $29.0M | $118.7M |
| 総負債低いほど良い | $68.4M | $432.2M |
| 株主資本純資産 | $186.7M | $452.4M |
| 総資産 | $434.8M | $582.5M |
| 負債/資本比率低いほどレバレッジが低い | 0.37× | 0.96× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $29.0M | $118.7M | ||
| Q3 25 | $20.4M | $107.5M | ||
| Q2 25 | $21.3M | $94.3M | ||
| Q1 25 | $27.3M | $89.1M | ||
| Q4 24 | $27.3M | $96.6M | ||
| Q3 24 | $24.3M | $83.8M | ||
| Q2 24 | $28.5M | $66.1M | ||
| Q1 24 | $28.2M | $82.1M |
| Q4 25 | $68.4M | $432.2M | ||
| Q3 25 | $69.4M | $433.3M | ||
| Q2 25 | $70.3M | $434.4M | ||
| Q1 25 | $71.3M | $435.3M | ||
| Q4 24 | $72.2M | $436.2M | ||
| Q3 24 | $73.1M | $437.2M | ||
| Q2 24 | $74.1M | $438.1M | ||
| Q1 24 | — | $439.0M |
| Q4 25 | $186.7M | $452.4M | ||
| Q3 25 | $178.5M | $448.1M | ||
| Q2 25 | $172.5M | $442.4M | ||
| Q1 25 | $159.8M | $433.5M | ||
| Q4 24 | $155.2M | $429.5M | ||
| Q3 24 | $161.5M | $423.1M | ||
| Q2 24 | $150.7M | $418.4M | ||
| Q1 24 | $145.4M | $412.0M |
| Q4 25 | $434.8M | $582.5M | ||
| Q3 25 | $430.4M | $582.2M | ||
| Q2 25 | $435.7M | $574.8M | ||
| Q1 25 | $433.3M | $571.4M | ||
| Q4 24 | $433.3M | $581.6M | ||
| Q3 24 | $454.1M | $578.6M | ||
| Q2 24 | $440.4M | $571.4M | ||
| Q1 24 | $446.8M | $566.7M |
| Q4 25 | 0.37× | 0.96× | ||
| Q3 25 | 0.39× | 0.97× | ||
| Q2 25 | 0.41× | 0.98× | ||
| Q1 25 | 0.45× | 1.00× | ||
| Q4 24 | 0.47× | 1.02× | ||
| Q3 24 | 0.45× | 1.03× | ||
| Q2 24 | 0.49× | 1.05× | ||
| Q1 24 | — | 1.07× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $18.8M | $40.9M |
| フリーキャッシュフロー営業CF - 設備投資 | $18.0M | $33.5M |
| FCFマージンFCF / 売上 | 27.7% | 47.1% |
| 設備投資強度設備投資 / 売上 | 1.1% | 10.4% |
| キャッシュ転換率営業CF / 純利益 | 5.17× | 28.39× |
| 直近12ヶ月FCF直近4四半期 | $37.9M | $56.8M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $18.8M | $40.9M | ||
| Q3 25 | $8.2M | $17.7M | ||
| Q2 25 | $1.9M | $4.6M | ||
| Q1 25 | $12.7M | $5.7M | ||
| Q4 24 | $18.1M | $59.7M | ||
| Q3 24 | $5.3M | $17.6M | ||
| Q2 24 | $10.7M | $15.9M | ||
| Q1 24 | $12.9M | $9.4M |
| Q4 25 | $18.0M | $33.5M | ||
| Q3 25 | $7.1M | $16.4M | ||
| Q2 25 | $884.0K | $2.9M | ||
| Q1 25 | $11.9M | $4.0M | ||
| Q4 24 | $17.3M | $53.0M | ||
| Q3 24 | $3.5M | $16.3M | ||
| Q2 24 | $9.9M | $14.0M | ||
| Q1 24 | $12.3M | $6.8M |
| Q4 25 | 27.7% | 47.1% | ||
| Q3 25 | 11.7% | 22.4% | ||
| Q2 25 | 1.5% | 4.0% | ||
| Q1 25 | 19.2% | 5.3% | ||
| Q4 24 | 27.6% | 73.2% | ||
| Q3 24 | 6.0% | 20.8% | ||
| Q2 24 | 16.9% | 17.8% | ||
| Q1 24 | 21.0% | 8.6% |
| Q4 25 | 1.1% | 10.4% | ||
| Q3 25 | 1.8% | 1.8% | ||
| Q2 25 | 1.7% | 2.2% | ||
| Q1 25 | 1.2% | 2.3% | ||
| Q4 24 | 1.3% | 9.1% | ||
| Q3 24 | 3.1% | 1.7% | ||
| Q2 24 | 1.5% | 2.4% | ||
| Q1 24 | 0.9% | 3.3% |
| Q4 25 | 5.17× | 28.39× | ||
| Q3 25 | 3.32× | 4.45× | ||
| Q2 25 | 0.40× | 0.97× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 10.28× | ||
| Q3 24 | 1.54× | 18.22× | ||
| Q2 24 | 3.17× | 4.29× | ||
| Q1 24 | — | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
